Dash Bio is solving rate-limiting issues in drug development. Leveraging robotics and an integrated software stack, Dash has rebuilt the lab CRO from the ground up. The company offers GLP-compliant bioanalysis with 10x faster turnarounds and highly reproducible results at transparent, fixed price points, replacing an industry still run largely on manual processes and opaque timelines.
Now operating out of a 24,000 sq. ft. GLP site in Waltham, MA, Dash supports ELISA, MSD, LC-MS, qPCR, and ddPCR assays, helping sponsors bypass traditional delays and accelerate their development timelines. Dash works with leading biopharma companies including Alnylam, Moderna, Merck, Novo Nordisk, Sanofi, Bristol Myers Squibb, and Flagship Pioneering, supporting programs from preclinical through clinical development.
The company closed a $30 million Series A in August 2026, funding expanded lab capacity and continued build-out of the software infrastructure behind its speed and reproducibility advantage.
